Medical Innovation Exchange

AbbVie, following in footsteps of Lilly and Takeda, pays Anima $42M to go after undruggable targets

https://www.fiercebiotech.com/biotech/abbvie-following-footsteps-lilly-and-takeda-pays-anima-42m-go-after-undruggable-targets

Leave a Comment

Your email address will not be published. Required fields are marked *

Leave the field below empty!